Prognosis

Advances in treatment allow a near-normal lifestyle and lifespan for most patients with haemophilia A and B. Preservation of joint function may be achieved, even in patients with severe haemophilia A or B, with the use of prophylaxis (defined as the regular, continuous administration of a haemostatic agent/agents, with the goal of preventing bleeding in people with haemophilia while allowing them to lead active lives and achieve quality of life comparable to non-haemophilia individuals).​[38]​

Complications of haemophilia, such as chronic joint arthropathy, remain a common occurrence in developing countries, primarily in those who are not receiving prophylactic factor infusions or have developed inhibitors to factor VIII or factor IX. Several studies have shown prophylaxis with doses as low as 5 to 10 IU/kg 2 to 3 times a week substantially reduced the bleeding rate (compared with on-demand therapy), with improvement of quality of life allowing for better school attendance, gainful employment, and community participation.[143][144][145][146][147] Low-dose prophylaxis should therefore be advocated for patients in developing countries.

Use of this content is subject to our disclaimer